Trial Profile
Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC). A Phase II Study of GV 1001 Telomerase Peptide Vaccination in Patients With Locally Advanced NSCLC.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2012
Price :
$35
*
At a glance
- Drugs Tertomotide (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Nov 2011 Result have been published in the journal Clinical Cancer, according to a KAEL-GemVax media release.
- 23 Sep 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 23 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.